

Amendments to the Claims

RECEIVED

Page 4

I. **Amendments** APR 2 9 2003

Please amend claims 1 and 6 as indicated below.

TECH CENTER 1600/2900

II. The Claims of the Application

- Claim 1. (Currently amended) A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a muscle toxin selected from the group consisting of: ricin and abrin, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor (nAchR).
- Claim 2. (Original) The method of claim 1, wherein the antibody is a monoclonal antibody.
- Claim 3. (Original) The method of claim 1, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.
- Claim 4. (Currently amended) The method of claim 1, wherein said muscle toxin is ricin.
- Claim 5. (Original) The method of claim 1, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia. hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.
- Claim 6. (Currently amended) A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically

Reply to the Official Action of February 26, 2003 In Re. Patent Appln. of Hott, J.S. et al. Serial No. 10/005,512

> effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a galactose binding moiety and a muscle toxin selected from the group consisting of: ricin-A and abrin-A, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor (nAchR).

Page 5

- (Original) The method of claim 6, wherein said galactose binding moiety is Claim 7. selected from the group consisting of: ricin-B and abrin-B.
- Claim 8. (Original) The method of claim 6, wherein the antibody is a monoclonal antibody.
- Claim 9. (Original) The method of claim 6, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.
- Claim 10. (Original) The method of claim 6, wherein said toxin is ricin.
- Claim 11. (**Original**) The method of claim 6, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.
- Claim 12. (Currently amended) An immunotoxin conjugate, comprising an antibody conjugated to a muscle toxin selected from the group consisting of: ricin and abrin, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a mammalian nicotinic acetylcholine receptor.
- Claim 13. (Original) The immunotoxin of claim 12, wherein the antibody is a monoclonal antibody.

Reply to the Official Action of February 26, 2003 Page 6

In Re. Patent Appln. of Hott, J.S. *et al.* Serial No. 10/005,512

- Claim 14. (**Original**) The immunotoxin conjugate of claim 12, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.
- Claim 15. (**Currently amended**) The immunotoxin conjugate of claim 12, wherein said <u>muscle</u> toxin is ricin.